29-May-2026
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Wed, 13-May 4:01 PM ET)
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
Globe Newswire (Tue, 12-May 9:31 AM ET)
Globe Newswire (Wed, 6-May 7:00 AM ET)
Business Wire (Mon, 4-May 12:55 PM ET)
Newsfile (Mon, 4-May 11:31 AM ET)
Globe Newswire (Sat, 2-May 4:00 PM ET)
Newsfile (Fri, 1-May 7:12 PM ET)
Globe Newswire (Fri, 1-May 12:01 PM ET)
Globe Newswire (Fri, 1-May 9:00 AM ET)
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Aquestive Therapeutics trades on the NASDAQ stock market under the symbol AQST.
As of May 29, 2026, AQST stock price was flat at $4.02 with 1,254,408 million shares trading.
AQST has a beta of 0.38, meaning it tends to be less sensitive to market movements. AQST has a correlation of 0.00 to the broad based SPY ETF.
AQST has a market cap of $504.31 million. This is considered a Small Cap stock.
Last quarter Aquestive Therapeutics reported $14 million in Revenue and -$.07 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.06.
In the last 3 years, AQST traded as high as $7.55 and as low as $1.25.
The top ETF exchange traded funds that AQST belongs to (by Net Assets): VTI, IWM, VXF, XPH, IWN.
AQST has outperformed the market in the last year with a return of +44.1%, while the SPY ETF gained +29.5%. However, in the most recent history, AQST shares have underperformed the stock market with its stock returning +0.5% in the last 3 month period and -3.6% for the last 2 week period, while SPY has returned +10.5% and +2.3%, respectively.
AQST support price is $3.87 and resistance is $4.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AQST shares will trade within this expected range on the day.
